BRAF oncogenic mutants evade autoinhibition through a common mechanism
Authors:
- Hugo LavoieHLHugo Lavoie
- Ting JinTJTing Jin
- Driss LajoieDLDriss Lajoie
- Marion DecossasMDMarion Decossas
- Patrick GendronPGPatrick Gendron
- Bing WangBWBing Wang
- Frantisek FilandrFFFrantisek Filandr
- Malha SahmiMSMalha Sahmi
- Chang Hwa JoCJChang Hwa Jo
- Sandra WeberSWSandra Weber
- Geneviève ArseneaultGAGeneviève Arseneault
- 29 May 2025
- journal article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6750) , eadp2742
Abstract
Uncontrolled activation of the rat sarcoma (RAS)–extracellular signal–regulated kinase (ERK) pathway drives tumor growth, often because of oncogenic BRAF mutations. BRAF regulation, involving monomeric autoinhibition and activation by dimerization, has been intensely scrutinized, but mechanisms enabling oncogenic mutants to evade regulation remain unclear. By using cryo–electron microscopy, we solved the three-dimensional structures of the three oncogenic BRAF mutant classes, including the common V600E variant. These mutations disrupted wild-type BRAF's autoinhibited state, mediated by interactions between the cysteine-rich domain and kinase domain, thereby shifting the kinase domain into a preactivated conformation. This structural change likely results from helix αC displacement. PLX8394, a BRAF inhibitor that stabilizes helix αC in an inactive conformation, restored the autoinhibited conformation of oncogenic BRAF, explaining the properties of this class of compounds.Keywords
This publication has 51 references indexed in Scilit:
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF SignalingCancer Cell, 2016
- Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2Cancer Cell, 2016
- BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic InhibitionCancer Cell, 2015
- Transient Mammalian Cell Transfection with Polyethylenimine (PEI)2013
- Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor DimerizationCell, 2012
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Mechanism for Activation of the EGF Receptor Catalytic Domain by the Juxtamembrane SegmentCell, 2009
- Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor SensitivityCancer Cell, 2007
- High resolution, high-throughput amide deuterium exchange-mass spectrometry (DXMS) determination of protein binding site structure and dynamics: Utility in pharmaceutical designJournal of Cellular Biochemistry, 2001